Kynam Capital Management
Latest statistics and disclosures from Kynam Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, VRTX, CLDX, SNDX, SPY, and represent 55.91% of Kynam Capital Management's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$109M), VRTX (+$108M), INSM (+$67M), DVAX (+$32M), VRDN (+$21M), CLDX (+$18M), BCRX (+$14M), ALNY (+$10M), COGT (+$6.4M), BNR (+$6.3M).
- Started 5 new stock positions in CGON, INSM, ALNY, BNR, SPY.
- Reduced shares in these 4 stocks: LQDA (-$16M), CORT (-$15M), PTGX (-$12M), Burning Rock Biotech Adr Rep Ord (-$7.0M).
- Sold out of its positions in Burning Rock Biotech Adr Rep Ord, CORT.
- Kynam Capital Management was a net buyer of stock by $353M.
- Kynam Capital Management has $1.3B in assets under management (AUM), dropping by 35.68%.
- Central Index Key (CIK): 0001907884
Tip: Access up to 7 years of quarterly data
Positions held by Kynam Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Kynam Capital Management
Kynam Capital Management holds 26 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 16.8 | $218M | 2.0M | 108.29 |
|
|
| Vertex Pharmaceuticals Incorporated Put Option (VRTX) | 11.9 | $155M | +230% | 330k | 468.72 |
|
| Celldex Therapeutics Com New (CLDX) | 9.7 | $125M | +16% | 3.4M | 37.01 |
|
| Syndax Pharmaceuticals (SNDX) | 9.1 | $118M | 5.7M | 20.53 |
|
|
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 8.4 | $109M | NEW | 200k | 545.50 |
|
| Dynavax Technologies Corp Com New (DVAX) | 6.1 | $80M | +67% | 7.1M | 11.23 |
|
| Cogent Biosciences (COGT) | 6.0 | $78M | +8% | 9.3M | 8.43 |
|
| Insmed Com Par $.01 Call Option (INSM) | 5.2 | $67M | NEW | 1.0M | 67.00 |
|
| Vaxcyte (PCVX) | 4.4 | $57M | 753k | 75.51 |
|
|
| Vera Therapeutics Cl A (VERA) | 4.3 | $56M | 1.5M | 36.18 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 4.2 | $55M | +35% | 8.8M | 6.18 |
|
| Protagonist Therapeutics (PTGX) | 2.1 | $28M | -30% | 800k | 34.65 |
|
| 2seventy Bio Common Stock (TSVT) | 1.8 | $23M | 6.0M | 3.85 |
|
|
| Miragen Therapeutics (VRDN) | 1.8 | $23M | +1207% | 1.8M | 13.01 |
|
| Wave Life Sciences SHS (WVE) | 1.5 | $20M | 4.0M | 4.99 |
|
|
| Travere Therapeutics (TVTX) | 1.3 | $17M | 2.0M | 8.22 |
|
|
| Liquidia Corporation Com New (LQDA) | 0.8 | $11M | -59% | 917k | 12.00 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 0.8 | $11M | 1.6M | 6.52 |
|
|
| Alnylam Pharmaceuticals Put Option (ALNY) | 0.8 | $10M | NEW | 43k | 243.00 |
|
| Tyra Biosciences (TYRA) | 0.7 | $9.1M | +10% | 567k | 15.99 |
|
| Amarin Corp Spons Adr New (AMRN) | 0.6 | $8.4M | 12M | 0.69 |
|
|
| Burning Rock Biotech Sponsored Ads (BNR) | 0.5 | $6.3M | NEW | 975k | 6.45 |
|
| Sutro Biopharma (STRO) | 0.5 | $5.9M | 2.0M | 2.93 |
|
|
| Acelyrin (SLRN) | 0.3 | $3.7M | +109% | 831k | 4.41 |
|
| Caribou Biosciences (CRBU) | 0.2 | $2.7M | +54% | 1.6M | 1.64 |
|
| Cg Oncology (CGON) | 0.1 | $1.7M | NEW | 54k | 31.57 |
|
Past Filings by Kynam Capital Management
SEC 13F filings are viewable for Kynam Capital Management going back to 2021
- Kynam Capital Management 2024 Q2 filed Aug. 14, 2024
- Kynam Capital Management 2024 Q1 filed May 15, 2024
- Kynam Capital Management 2023 Q4 filed Feb. 14, 2024
- Kynam Capital Management 2023 Q3 filed Nov. 14, 2023
- Kynam Capital Management 2023 Q2 filed Aug. 14, 2023
- Kynam Capital Management 2023 Q1 filed May 15, 2023
- Kynam Capital Management 2022 Q4 filed Feb. 14, 2023
- Kynam Capital Management 2022 Q3 filed Nov. 14, 2022
- Kynam Capital Management 2022 Q2 filed Aug. 15, 2022
- Kynam Capital Management 2022 Q1 filed May 13, 2022
- Kynam Capital Management 2021 Q4 filed Feb. 14, 2022